Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers

Parvin Zakeri-Milani; Hadi Valizadeh; Ziba Islambulchilar; Mahboob Nemati

doi:10.1055/s-0031-1296252

Arzneimittelforschung, Table of Contents

Arzneimittelforschung 2010; 60(2): 76-80
DOI: 10.1055/s-0031-1296252

Antihypertensives

Editio Cantor Verlag Aulendorf (Germany)

Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers

Authors

Parvin Zakeri-Milani

¹Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, (Iran)

²Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, (Iran)
Hadi Valizadeh

¹Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, (Iran)

³Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, (Iran)
Ziba Islambulchilar

¹Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, (Iran)

⁴Department of Pharmaceutics, Faculty of Pharmacy, Zanjan University of Medical Sciences, Zanjan, (Iran)
Mahboob Nemati

¹Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, (Iran)

⁵Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, (Iran)

Abstract

Valsartan (CAS 137862-53-4) is an antihypertensive drug belonging to the family of angiotensin II receptor antagonists acting at the AT₁ receptor, which mediates all known effects of angiotensin II on the cardiovascular system. In the present study, the pharmacokinetic parameters of two oral formulations of valsartan tablets were compared in a randomized, single oral dose, two-treatment crossover design in 24 healthy male volunteers under fasting conditions. After an overnight fast, the volunteers received 80 mg valsartan. Blood samples were collected up to 48 h and drug concentrations were determined by a reverse-phase HPLC method with fluorescence detection. Various pharmacokinetic parameters were determined from the plasma concentration-time curves of both formulations. The obtained values for test and reference products were 3 067.7 ± 1 281.7 and 3 304.3 ± 1 196.4 ng/ml for C_max; 17 834.4 ± 7 083.8 and 18319.1 ± 7 800.7 ng · h/ml for AUC_0–48; 18825.7 ± 7 553.2 and 19 172.2 ± 8 307.2 ng · h/ml for AUC_0–∞, respectively. The 90% confidence intervals obtained by analysis of variance were 86.84–100.87% for C_max and 93.43–115.54% for AUC_0–t, which are within the acceptance range of 80–125%. Therefore it can be concluded that both products are bioequivalent in terms of rate and extent of drug absorption and therefore interchangeable.

Key words

Angiotensin II receptor antagonist - Antihypertensive - CAS 137862-53-4 - Valsartan, bioavailability, bioequivalence

Full Text

References

References
1 Li H, Wang Y, Jiang Y, Tang Y, Wang J, Zhao L et al. A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 852 (1–2)) 436-42
2 Remuzzi A, Perico N, Remuzzi G.. Pharmacological and clinical profile of valsartan. Drugs Today (Barc). 1998; 34 (11) 973-986
3 Nie J, Zhang M, Fan Y, Wen Y, Xiang B, Feng YQ. Biocompatible in-tube solid-phase microextraction coupled to HPLC for the determination of angiotensin II receptor antagonists in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 828 (1–2) 62-9
4 van Zwieten PA. Angiotensin II receptor antagonists (AT₁ blockers, ARBs, Sartans): similarities and differences. Netherlands Heart J. 2006; 14 (11) 381-7
5 Yan J, Wang W, Chen L, Chen S. Electrochemical behavior of valsartan and its determination in capsules. Colloids Surf B Biointerfaces. 2008; 67 (2) 205-9
6 Koseki N, Kawashita H, Hara H, Niina M, Tanaka M, Kawai R et al. Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2007; 43 (5) 1769-74
7 Flynn JT, Meyers KE, Neto JP, dePaulaMeneses R, Zurowska A, Bagga A et al. Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension. 2008; 52 (2) 222-8
8 IsrailiZ H. Clinical pharmacokinetics of angiotensin II (AT₁) receptor blockers in hypertension. J Hum Hypertens. 2000; 14 (01) S73-86
9 Flesch G, Muller R, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol. 1997; 52 (2) 115-20
10 Waldmeier F, Flesch G, Muller R, Winkler T, Kriemler HP, Bühlmayer R et al. Pharmacokinetic, disposition and bio-transformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica. 1997; 27 (1) 59-71
11 Sweetman S. Martindale: The Complete Drug Reference. London: Pharmaceutical Press; 2007
12 Macek J, Klima J, Ptacek P. Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography. J Chromatogr B Anαlyt Technol Biomed Life Sci. 2006; 832 (1) 169-72
13 Zakeri-Milani P, Barzegar-Jalali M, Tajerzadeh H, Azarmi Y, Valizadeh H. Simultaneous determination of naproxen, ketoprofen and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation. J Pharm Biomed Anal. 2005; 39 (3–4) 624-30
14 Valizadeh H, Zakeri-Milani P, Islambulchilar Z, Tajerzadeh H. A simple and rapid high-performance liquid chromatography method for determining furosemide, hydrochlorothiazide, and phenol red: applicability to intestinal permeability studies. J AOAC Int. 2006; 89 (1) 88-93
15 Nemati M, Valizadeh H, Ansarin M, Ghaderi F. Development of a simple and sensitive high-performance liquid chromatography method for determination of glucosamine in pharmaceutical formulations. J AOAC Int. 2007; 90 (2) 354-7
16 Miller JC, Miller JN. Statistics for Analytical Chemistery. Chichester (UK): Ellis Horwood Ltd; 1993
17 FDA Guidance for industry, bioavailability and bioequivalence studies for orally administered drug products; General considerations. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) 2003 [cited 2009 May 16]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf
18 Zakeri-Milani P, Valizadeh H. Comparative bioavailability study of two olanzapine formulations administered orally in healthy male volunteers. Pharm World Sci. 2008; 30 (5) 702-3
19 Zakeri-Milani P, Valizadeh H, Islambulchilar Z. Comparative bioavailability study of two Cefixime formulations administered orally in healthy male volunteers. Arzneimittelforschung. 2008; 58 (2) 97-100
20 Valizadeh H, Barghi L, Jalilian H, Islambulchilar Z, Zakeri-Milani P. Bioequivalence of fexofenadine tablet formulations assessed in healthy Iranian volunteers. Arzneimittelforschung. 2009; 59 (7) 345-9
21 Zakeri-Milani P, Valizadeh H, Ghanbarzadeh S, Nemati M. Pharmacokinetics and comparative bioavailability study of two clarithromycin suspensions following administration of a single oral dose to healthy volunteers. Arzneimittelforschung. 2009; 59 (8) 429-32
22 Asiri YA, Al-Said MS, Al-Khamis KI, Niazy EM, El-Sayed YM, Al-Rashood KA et al. Comparative bioavailability study of Cefixime (equivalent to 100 mg/5 ml) suspension (Winex vs. Suprax) in healthy male volunteers. Int J Clin Pharmacol Ther. 2005; 43 (10) 499-504
23 Schall R, Luus HG. Comparison of absorption rates in bioequivalence studies of immediate release drug formulations. Int J Clin Pharmacol Ther Toxicol. 1992; 30 (5) 153-9